Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Prostate Cancer
Interventions
DRUG

INM176

The active ingredient INM176 was prepared using a proprietary technology to extract AGN with ethanol and powderize with cellulose into a finished granular powder product that is 1/5 the weight of the raw herbal root. This product was chosen because its close match with the AGN extracts studied in the TRAMP model in the phytochemical profiles. It will be donated from the manufacturer Nutragen Co., Ltd. Korea.

Trial Locations (1)

17033

RECRUITING

Penn State Cancer Institute, Hershey

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER